Item 8.01 Other Events.
On May 10, 2021, NuGenHealth, LLC, ("NuGenHealth"), a subsidiary of Generex
Biotechnology Corporation, signed a services agreement with Westside Medicine &
Cardiology, P.C. an Ohio professional corporation ("WM&C") to provide a software
and services solution to physician practices enabling them to engage their
patients in Remote Patient Monitoring (RPM) and Chronic Care Management (CCM)
services that are recommended and reimbursed by the Centers of Medicare and
Medicaid Services (CMS) (the "Agreement").
Under the terms of the Agreement, NuGenHealth will implement the company's
software system and connected metabolic monitoring devices, and will enable
physician practices to provide RPM and CCM services to Medicare patients with
chronic medical conditions who are under the care of WM&C physicians. WM&C will
bill CMS for the RPM and CCM services, and will pay software and service fees to
NuGenHealth.
About NuGenHealth, LLC
NuGenHealth, LLC is an Arizona Limited Liability Company, a subsidiary of
Generex Biotechnology Corporation, a publicly traded company, and is engaged to
provide a software and services solution for physicians and medical practices
for the purpose of providing the Connected Care Solutions for patient engagement
and more specifically, Remote Patient Monitoring and Chronic Care Management.
Forward-Looking Statements
Statements in this report may contain certain forward-looking statements. All
statements included concerning activities, events or developments that the
Generex expects, believes or anticipates will or may occur in the future are
forward-looking statements. Actual results could differ materially from the
results discussed in the forward-looking statements. Forward-looking statements
are based on current expectations and projections about future events and
involve known and unknown risks, uncertainties and other factors that may cause
actual results and performance to be materially different from any future
results or performance expressed or implied by forward-looking statements. Known
risks and uncertainties also include those identified from time to time in the
reports filed by Generex with the Securities and Exchange Commission, which
should be considered together with any forward-looking statement. No
forward-looking statement is a guarantee of future results or events, and one
should avoid placing undue reliance on such statements. Generex undertakes no
obligation to update publicly any forward-looking statements, whether as a
result of new information, future events or otherwise. Generex cannot be sure
when or if it will be permitted by regulatory agencies to undertake additional
clinical trials or to commence any particular phase of clinical trials. Because
of this, statements regarding the expected timing of clinical trials or ultimate
regulatory approval cannot be regarded as actual predictions of when Generex
will obtain regulatory approval for any "phase" of clinical trials or when it
will obtain ultimate regulatory approval by a particular regulatory agency.
Generex claims the protection of the safe harbor for forward-looking statements
that is contained in the Private Securities Litigation Reform Act. Additional
information on these and other risks, uncertainties and factors is included in
the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q,
Current Reports on Form 8- K and other documents filed with the SEC.
1
© Edgar Online, source Glimpses
GENEREX BIOTECHNOLOGY CORPORATION 
